Phase 3 trial shows personalized mRNA vaccine reduces melanoma recurrence by over 40 percent

A new mRNA vaccine reduced the risk of melanoma recurrence by more than 40 percent in a Phase 3 trial, Wired reports today. The result points to a turning point for personalized cancer immunotherapy, with mRNA showing clinical benefit beyond infectious disease. It also raises the prospect of a new standard of care for high risk melanoma patients if confirmed by regulators and peer review.

According to Wired, the shot is custom built from each patient’s tumor profile, aiming to prime the immune system against returning cancer. Phase 3 efficacy topped the 40 percent threshold in preventing recurrence, though full datasets, safety profiles, and overall survival readouts have not yet been detailed. Watch for the full data presentation, peer reviewed publication, and any regulatory filings that indicate when patients could gain access. [Developing. This article will be updated.]